Figure S5 from A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma

Key Points

• The combination of RMC-7977 and palbociclib stimulates long-term tumor control in pancreatic ductal adenocarcinoma.
• CD40 agonist enhances treatment efficacy, improving responses to the multi-selective inhibitor therapy.
• This research utilizes a multimodal approach to target tumor progression and immune response mechanisms.
• Findings suggest that managing immune equilibrium through therapy may advance treatment strategies for pancreatic cancer.